Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex

Advanced MRSA Test Receives US FDA Approval

By Labmedica International staff writers
Posted on 30 Jan 2014
Image: The fully automated BD MAX System (Photo courtesy of Becton, Dickinson and Company).
Image: The fully automated BD MAX System (Photo courtesy of Becton, Dickinson and Company).
Clinical laboratories in the United States can now take advantage of a dedicated assay for the rapid diagnosis of MRSA (methicillin-resistant Staphylococus aureus) infections.

The global medical and biotechnological company Becton, Dickinson and Company (Franklin Lakes, NJ, USA) announced that the MAX MRSA XT Assay, which is marketed by their BD Diagnosis subsidiary, had received [US] Food and Drug Administration (FDA) 510(k) approval for use as a diagnostic test.

The MAX MRSA XT Assay is intended for use on the fully automated BD MAX System and complements the MAX StaphSR Assay, which reports results for both Staphylococus aureus (SA) and MRSA.

Both assays employ BD's eXTended Detection Technology to identify a broad range of SA strains including mecA and mecC dropout mutants and new strains of MRSA that may not be detected by other assays.

"Assay design is critical to detect MRSA accurately and ensure appropriate infection control interventions are applied," said Dr. Patrick Murray, worldwide director of scientific affairs at BD Diagnostics. "The BD MAX MRSA XT Assay helps improve patient safety by providing hospitals with a new solution to detect the latest strains of this drug-resistant superbug."

Related Links:

Becton, Dickinson and Company



Genetic Tests

view channel
Image: The QuantiTect Reverse Transcription Kit (Photo courtesy of Qiagen)

Blood Tests Predict Risk of Sudden Cardiac Death

A simple blood test can predict a person's risk for sudden cardiac death, enabling physicians to quickly and accurately assess a patient's need for an implantable cardiac defibrillator (ICD).... Read more


view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more


view channel

Gene Profile Predicts Risk of Bladder Cancer Recurrence

A genomic study has pinpointed several markers that identify bladder cancer patients at risk of recurrence and that may be indicators of overall survival status. Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment.... Read more

Industry News

view channel

Beckman Coulter and hc1.com Enter Strategic Partnership for Innovative Healthcare Cloud System

The diagnostics division of Beckman Coulter (Brea, CA, USA) and hc1.com (Indianapolis, IN, USA) have announced a partnership to bring an innovative healthcare cloud-technology system to clinical laboratories. The system, hc1.com's "Healthcare Relationship Cloud," helps turn large amounts of clinical data into actionable... Read more
Copyright © 2000-2014 Globetech Media. All rights reserved.